Joined Weave Bio's $20M Series A, led by USVP, to accelerate pharma regulatory workflows with AI.
Weave Bio’s AI-native regulatory platform transforms how teams prepare and manage complex dossiers across the therapeutic life cycle
Weave Bio’s AI-native regulatory platform transforms how teams prepare and manage complex dossiers across the therapeutic life cycle. It supports regulatory workflows using AI technology to enhance the efficiency and accuracy of submissions.